Here's Why Array BioPharma Inc. Fell 13.7% in July
Shares of Array BioPharma (NASDAQ: ARRY), a cancer-focused clinical-stage biotech, dropped nearly 14% in July, according to data from S&P Global Market Intelligence.
Here's a review of the two company announcements made during the month:
Given the upbeat news items, I'm once again left scratching my head as to why shares fell so much last month.
Source: Fool.com